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Immunochemical Localization of Keratan Sulfate
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Keith M. Meek,1 and Bruce Caterson4
PURPOSE. To evaluate the use of neoepitope monoclonal anti-
body BKS-1, which recognizes keratanase-generated keratan
sulfate (KS) stubs on keratan sulfate proteoglycans in human
cornea, limbus, and sclera.
METHODS. BKS-1 specifically recognizes a keratanase-generated
neoepitope [N-acetyl-glucosamine-6-sulfate (GlcNAc-6-S)] at
the nonreducing terminal of corneal and skeletal KS glycosami-
noglycan chains. It was produced by using keratanase-digested
KS peptides from bovine cartilage aggrecan as the immunizing
antigen. BKS-1 was used in conjunction with 5D4 to analyze
the KS distribution in human cornea, limbus, and sclera using
Western blotting, immunohistochemistry, and electron micros-
copy.
RESULTS. 5D4 Western blot analysis displayed a diffuse staining
pattern, and it was difficult to distinguish differences among
cornea, sclera, and limbus. However, BKS-1 showed differ-
ences in KS levels, with higher levels in the cornea and lower
levels in the limbus and sclera. Ultrastructural studies showed
that the monoclonal antibody (mAb) BKS-1 neoepitope was
not observed in the epithelium or basement membrane; how-
ever, 5D4 was present in these layers. Large quantities of both
antibodies were present in Bowman’s layer, stroma, and Des-
cemet’s membrane, but the quantity of 5D4 was significantly
higher (P 0.001) than the quantity of BKS-1 in all these layers
of the cornea.
CONCLUSIONS. mAb 5D4 recognizes oversulfated structures
within KS chains, whereas BKS-1 recognizes a single neo-
epitope on KS after keratanase digestion of monosulfated KS
disaccharides. With the use of BKS-1, the authors identified a
more clearly defined pattern for KS distribution in the cornea
than was seen with 5D4. The presence of a large quantity of
BKS-1 immunostaining in the cornea suggests that KS-substi-
tuted proteoglycans are more prevalent in the cornea than in
the limbus or sclera. (Invest Ophthalmol Vis Sci. 2008;49:
2424–2431) DOI:10.1167/iovs.06-1498
Corneal proteoglycans (PGs) are thought to play importantroles in collagen fibrillogenesis and matrix assembly and in
modifying the structure and function of collagen fibrils.1–3
They are macromolecules composed of a protein core with
covalently linked glycosaminoglycan side chains.4 Studies from
bovine,5 rabbit,6 chicken,7 monkey,8 and human9 corneas
show that the predominant components of the glycosamino-
glycans are keratan sulfate and dermatan sulfate, with smaller
amounts of heparan sulfate. Experiments suggest that the core
proteins on the keratan sulfate proteoglycan (KS-PG) act in
conjunction with type V collagen to regulate the diameters of
the collagen fibrils,10 whereas the sulfated gylcosaminoglycans
appear to regulate fibril spacing.11 KS is associated with posi-
tive staining bands a and c12 along the fibril. Dermatan sulfate
may also be important for interfibrillar spacing and lamellar
adhesion of collagen13 and is associated with bands d and e.12
Keratan sulfate proteoglycan (KS-PG), the most abundant
carbohydrate in the cornea, plays an important role in the
maintenance of corneal transparency.14,15 Three proteins, lu-
mican, keratocan, and mimican, have been reported to carry
keratan sulfate through N-linked oligosaccharides in the cor-
nea.16–19 The expression of these carrier proteins is regulated
during eye development, suggesting the importance of KS-PG
in corneal transparency.15,17–21
Several investigators have previously examined the struc-
ture and biosynthesis of KS.15,22–25 The general structure of KS
is based on repeating disaccharides of N-acetyl-lactosamine
(-3Gal1 to 4GlcNAc1-) in which most of the N-acetyl-glu-
cosamine (GlcNAc) residues and some of the galactose (Gal)
residues are sulfated on the C-6 position.26 Analysis of KS
isolated from porcine and calf cornea revealed a domain struc-
ture in which the linkage region is followed by one or two
unsulfated N-acetyl-lactosamine disaccharides, a constant num-
ber of monosulfated N-acetyl-lactosamine disaccharides fol-
lowed by anything from 6 to 36 disaccharides of disulfated
N-acetyl-lactosamine residues.27 Monoclonal antibodies (mAbs)
such as 5D4, raised in mice against skeletal KS from humans,28
have been helpful for a detailed analysis of the distribution of
KS in cornea. The antibody recognizes linear disulfated N-
acetyl-lactosamine disaccharides containing segments in
KS.29–32 This antibody does not allow for the discrimination of
different KS types (i.e., type 1 corneal KS vs. type 2 skeletal
KS). Although it is useful for the detection of oversulfated KS
chains, it is not suitable for selective quantification of tissue-
derived KS or diseased-derived KS. The new mAb BKS-1 rec-
ognizes a neoepitope containing the N-acetylglucosamine-6-
sulfate at the nonreducing terminal of KS GAG chains
predigested with keratanase.33
In the present study, we used the new KS-stub mAb BKS-1
specifically for keratanase-generated neoepitopes in KS-PGs
and compared it with the existing KS mAb 5D4 to investigate
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KS sulfation pattern motifs in normal corneal, limbal, and
scleral PGs.
METHODS
Tissue procurement and use were in accordance with the Declaration
of Helsinki and local regulations. The study was approved by the local
ethics committee, the Pontypridd & Rhondda NHS Trust Ethical Com-
mittee. Healthy donor eyes were obtained from the US National Dis-
ease Research Interchange.
Preparation and Screening of the Antigen
The monoclonal antibody BKS-1, which recognizes keratanase neo-
epitope KS stubs after the keratanase digestion of KS-PGs, was pro-
duced28 using KS peptides obtained from bovine nasal cartilage aggre-
can as the immunizing antigen.34 The KS peptides were produced after
trypsin digestion of bovine aggrecan, followed by pretreatment with
keratanase before further purification by size-exclusion and ion-ex-
change chromatography. Screening for mAbs that recognize the kera-
tanase-generated KS stubs involved ELISA plates coated with kerata-
nase-digested KS-PGs from bovine cartilage (skeletal KS) and cornea
(corneal KS). Immunopositive reactions were detected with skeletal
and corneal KS-PGs after keratanase pretreatment; however, negative
immunoreactivity for KS stubs was detected with positive recognition
of only skeletal KS or reactivity with undigested KS-PGs. After second-
ary screening using Western blot analysis against purified corneal
KS-PGs (keratocan and lumican predigested with keratanase vs. kera-
tanase II, which acted as positive and negative controls, respectively),
the mAb BKS-1 was identified as an IgM subclass with kappa light
chain.
Western Blot Analysis
Healthy human (donor age, 24–54 years) cornea, sclera, and limbus
were minced separately, and PGs were extracted twice for 24 hours
each in 10 (wt/vol) 4 M guanidine HCl containing protease inhibitors
(0.1 M 6-amino hexanoic acid, 5 mM benzamidine, 1 mM phenylmeth-
ylsulfonyl fluoride, 10 mM EDTA) in 0.05 M sodium acetate, pH 6.8.
Pooled guanidine extracts were dialyzed against 6 M urea, 0.1 M Tris,
0.1% Chaps, pH 6.8, at 4°C. Anion exchange chromatography was
carried out on both samples with bound PGs eluted in 2 M NaCl in 6 M
urea buffer, as described. Bound fractions were dialyzed to water,
lyophilized, and reconstituted in 200 L water. Dimethylmethylene
blue analysis was carried out to determine the sulfated glycosamino-
glycan (GAG) content of the samples. Volumes equivalent to 2 g GAG
were left undigested for 5D4 analysis and keratanase (Seikagaku, To-
kyo, Japan) with the use of 0.001 U keratanase/1 g GAG in 0.1 M
Tris-HCl, pH 6.8, for BKS-1 analysis. SDS-PAGE and Western blot anal-
ysis was carried on 4% to 20% Tris-glycine gradient gels using mAbs
5D4 and BKS-1 diluted 1:100 from neat hybridoma supernatant (ap-
proximately 0.1 g/mL).
With the use of corneal PG extracts, three experimental protocols
were conducted. First, using the undigested PG extracts from the
cornea, SDS-PAGE was performed, and transfers for Western blot
analysis for two lanes of each sample were undertaken. One lane was
immunostained with 5D4 and the other one with BKS-1. Second, the
corneal extracts were predigested with keratanase before SDS-PAGE
(two lanes) and transferred for Western blot analyses using mAbs 5D4
and BKS-1 on separate lanes. Third, corneal extracts were run on
SDS-PAGE and transferred to nitrocellulose, where they were subjected
to keratanase digestion “on the blot”; then one lane was immuno-
stained with 5D4 and the other lane with BKS-1.
Immunohistochemistry and Confocal Microscopy
Human corneal samples, fixed in 4% paraformaldehyde, were washed
briefly in PBS (pH 7.4), snap-frozen in tissue mountant (Cryo-Embed,
Bright Instrument, Huntingdon, UK), and cryosectioned at 10 m in
the midsagittal plane. Cryosections were circumscribed with a water-
repellent ring and then washed briefly in PBS (pH 7.4) before immu-
nofluorescence labeling. To generate its neoepitope site, monoclonal
antibody BKS-1 required predigestion with 0.4 U/mL keratanase in 10
mM Tris-HCl buffer (pH 7.4) for 1 hour at 37°C. Monoclonal antibody
5D4, which recognizes native KS chains, did not require a predigestion
step. After enzymatic digestion, sections were washed in PBS contain-
ing 0.001% Tween (wash buffer and antibody diluent) for 10 minutes
before blocking with normal goat serum (X0907; Dako, Carpinteria,
CA) at 1:20 dilution for 30 minutes at room temperature. Adjacent
tissue sections were then incubated overnight at 4°C with monoclonal
antibodies 5D4 and BKS-1 (tissue culture supernatants) at 1:50 dilution.
To check for nonspecific labeling, the primary antibody was replaced
with naive mouse immunoglobulin (X0931; Dako) or an antibody
diluent. After overnight incubation with primary antibody, sections
were washed in buffer for 10 minutes and incubated with a goat
anti-mouse FITC-conjugated secondary antibody (F0479; Dako) at 1:50
dilution for 1 hour at room temperature. Sections were washed for 10
minutes before counterstaining with 0.5 g/mL propidium iodide
(P-4170; Sigma) for 5 minutes at room temperature. Sections were
again washed before mounting under coverslips with mountant (H-
1000; Vectashield; Vector Laboratories, Burlingame, CA). Representa-
tive regions of cornea, limbus, and sclera were imaged on a confocal
laser scanning microscope (Sarastro 2000; GE Healthcare, Little Chal-
font, Buckinghamshire, UK). Specimens were scanned using a 25-mW
argon ion laser with appropriate excitation and emission filters for
simultaneous recording of fluorescein isothiocyanate (FITC; excitation
maximum, 494 nm; emission maximum, 518 nm) and propidium io-
dide (excitation maximum, 536 nm; emission maximum, 617 nm). To
reduce photobleaching, the laser output was attenuated using a 30%
neutral-density filter. Specimens were examined using 40 and 60
oil immersion objectives. Series of optical sections (512  512 pixels;
approximately 0.3-m thick) were taken through the tissue section at
a spacing of 0.7 m using software (Image Space; GE Healthcare)
running on a Silicon Graphics (Sunnyvale, CA) workstation. Represen-
tative optical sections from each stack were presented for output as
red-green overlays.
Immunoelectron Microscopy
Healthy human cornea, limbus, and sclera from three donors (age
range, 24–54 years) were used to study the immunolocalization of the
two different anti-KS antibodies. Small pieces of the tissue (1 mm3)
were fixed in freshly prepared 4% paraformaldehyde (PFA) in 0.1 M
phosphate for 2 hours at 4°C. Tissues were processed at low temper-
atures and were embedded in LR White at 20°C for 48 hours under
ultraviolet light, as described by Akhtar et al.35
Monoclonal antibodies BKS-1 and 5D4 were used as primary anti-
bodies to localize KS in the human and bovine corneas. The specificity
of the antibody to human antigens was tested and confirmed by the
supplier with immunologic assays. Antibodies were visualized with
10-nm goat anti-mouse and goat anti-mouse immunogold conjugate.
The immunogold conjugates, goat serum, bovine serum, and Tween-20
were supplied by Biocell (Cardiff, UK). Monoclonal antibody BKS-1
was produced using keratanase-digested KS peptides from bovine
cartilage aggrecan.
Ultrathin sections were predigested with 0.4 U/mL keratanase II in
10 mM Tris-HCl buffer (pH 7.4) for 1 hour at 37°C to generate a
neoepitope site for monoclonal antibody BKS-1. Monoclonal antibody
5D4, which recognizes native linear pentasulfated hexasaccharide por-
tions of KS chains, did not require a predigestion step. After enzymatic
digestion, sections were immunolabeled with the primary and second-
ary antibodies, as described by Akhtar et al.35 Sections were stained
with 2% aqueous uranyl acetate and lead citrate.
Sections were examined in a transmission electron microscope
(JEOL 1010; JEOL, Tokyo, Japan), and gold particles were counted in
the anterior, middle, and posterior zones of the stroma. Four images
were taken from different areas from each of these regions. The center
of the anterior zone was roughly within 20 m of the posterior edge of
IOVS, June 2008, Vol. 49, No. 6 Localization of Keratan Sulfate Proteoglycans 2425
Bowman’s layer, the center of the posterior zone was roughly within
20 m of the posterior edge of Descemet’s membrane, and the middle
zone was estimated to be roughly in the middle of the width of the
particular section under examination. This procedure was repeated
three times in each sample. Approximately 30,000 gold particles were
analyzed overall (AnalySIS; Soft Imaging System GmbH, Mu¨nster, Ger-
many). Data were analyzed (SPSS, Chicago, IL) by Kolmogorov-Smirnov
and Mann–Whitney U tests. Graphs were drawn using the Excel pro-
gram.
RESULTS
Distribution of 5D4 and BKS-1 in Normal Cornea,
Limbus, and Sclera
Without deglycosylation (), corneal KS-PGs (e.g., lumican
and keratocan) are heterogeneous and run as a smear on
SDS-PAGE gels. Keratanase digestion of KS-PGs results in only
partial deglycosylation (i.e., incomplete removal of the KS
GAGS), resulting in the smears on SDS-PAGE. However, the
amount of the smearing is reduced (e.g., Fig. 1B() compared
with Fig. 1B(). Definitive identification of lumican and ker-
atocan core proteins would require complete deglycosylation
of the KS-GAGs using keratanase, keratanase II, endo--galac-
tosidase, and N-glycanase digestion.
KS-PGs run as smears on Western blot analysis after SDS-
PAGE because they are heterogeneous in size given the varia-
tions in size and number of the KS chains on the PG core
protein. Thus, 5D4 immunostaining detects two major smears,
an upper one at approximately 200 kDa and a lower one at
approximately 75 kDa (Fig. 1A, lane 1). Predigestion with
keratanase reduces the intensity of the upper smear and causes
the lower smear to move to approximately 50 kDa, with an
additional smear at approximately 37 to 27 kDa (Fig. 1A, lane
2). The smaller molecular weight smears likely result from
KS-PG catabolites in the corneal extract. Keratocanase diges-
tion on the blot (Fig. 1, lane 3), before immunolocalization
with 5D4, produces essentially the same staining pattern as the
undigested Western blot (Fig. 1, lane 1). This means that
keratanase digestion has reduced the length of the KS chains
on the KS-PGs in the corneal extract and that some of the 5D4
epitope is present on the truncated KS-GAG chains still at-
tached to the PG core proteins. Immunostaining with BKS-1
was negative on the Western blot of native corneal KS-PGs that
had not been predigested with keratanase (Fig. 1, lane 4), but
strong immunostaining was detected with the KS-PGs after
keratanase pretreatment (Fig. 1, lane 5). These smears now
migrated at approximately 50 to 75 kDa, with some weaker
staining of KSPGs at approximately 200 kDa and even weaker
reactivity with KS-PGs migrating at 27 to 37 kDa. This result
indicated that the KSPGs migrating at approximately 200 kDa
and 27 to 37 kDa had little KS containing monosulfated N-
acetyl-lactosamine disaccharides that would allow keratanase
cleavage of the KS GAG chains and generation of the BKS-1
neoepitope. Immunostaining of the native corneal KSPGs after
keratanase treatment on the blot (Fig. 1, lane 6) showed essen-
tially the same staining pattern as that seen for the immuno-
staining with 5D4 under similar conditions (Fig. 1, lane 3). This
result indicated that both species/smears of KS-PGs, found at
approximately 200 kDa and approximately 75 kDa (Fig. 1,
lanes 1, 3, 6), contained some KS that was digestible with
keratanase and the production of the BKS-1 neoepitope.
Western blot analysis of corneal PG extracts showed that
5D4 staining without keratanase pretreatment (Fig. 1B, lane 1)
and BKS-1 after keratanase pretreatment (Fig. 1B, lane 2) dis-
played a heterogeneous distribution of KS-PGs in the molecular
weight range of 25 to 200 kDa. Similarly, the undigested ex-
tracts of limbus (Fig. 1C, lane 1) and sclera (Fig. 1D, lane 1)
stained with 5D4 showed a broad spectrum of molecular mass
KS-PGs from 25 to 200 kDa. In contrast, staining for BKS-1 on
limbus extracts (Fig. 1C, lane 2) and sclera extracts (Fig. 1D,
lane 2) after keratanase pretreatment showed a thicker, more
homogeneous smear ranging from 50 to 150 kDa. Thus, BKS-1
immunostaining showed a more subtle distribution pattern
than 5D4 and allowed the observation that the cornea contains
more keratanase-generated KS stubs than the sclera per GAG
loaded, with least the amount of these KS stubs present on
KSPGs in the limbus (Figs. 1B–D).
Immunohistochemistry and Confocal Microscopy
Negative controls showed no nonspecific labeling of the cor-
neal tissue (Fig. 2G). Comparison of immunofluorescent label-
ing patterns with monoclonal antibodies 5D4 and BKS-1 in the
cornea, limbus, and sclera showed that both antibodies gave
broadly similar distributions of KS labeling; however, the stain-
ing pattern with BKS-1 was more subtle and clearly defined
(Fig. 2). In the stroma of the cornea (Figs. 2A, 2B) and the
limbus (Figs. 2C, 2D), monoclonal antibodies 5D4 and BKS-1
strongly immunolocalized KS to sites between adjacent colla-
gen fiber bundles, manifest under epifluorescence optics as
highly elongated fibrillar streaks of punctuate immunolabel
(Figs. 2A, 2B, insets). In the cornea, KS labeling occurred
FIGURE 1. Western blot staining in normal cornea, sclera, and limbus
with 5D4 and BKS-1. BKS-1 showed a less diffuse pattern of staining
than 5D4 in the cornea (A), limbus (B), and sclera (C). Predigestion
with keratanase before SDS-PAGE or on the blot after SDS-PAGE is
indicated as (). No keratanase digestion before or after SDS-PAGE is
indicated as ().
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FIGURE 2. Immunofluorescent local-
ization of keratan sulfate with mono-
clonal antibodies 5D4 and BKS-1 in
normal human cornea, limbus, and
sclera. Scale bars are in ı`M. (A, B) In
cornea, keratan sulfate is immunolo-
calized throughout the stroma with
both KS antibodies; however, BKS-1
gives a more clearly defined staining
pattern. High-power observation of
KS immunostaining (inset) reveals
the presence of highly elongated
fibrillar streaks and rows of punctu-
ate KS immunolabel interposed be-
tween adjacent collagen fiber bun-
dles (arrows). (C, D) In limbus, both
KS antibodies give strong immunoflu-
orescent labeling of the posterior
two thirds of the tissue depth. (E, F)
In sclera, immunofluorescent label
for KS diminishes markedly and is
manifest in discrete regions between
collagen fiber bundles. Note that
monoclonal antibody BKS-1 gives a
more restricted labeling pattern than
that of 5D4. (G) Negative control.
IOVS, June 2008, Vol. 49, No. 6 Localization of Keratan Sulfate Proteoglycans 2427
throughout the depth of the tissue, but, in the limbus, KS was
virtually absent from the limbal conjunctiva (upper one third of
the tissue depth; Figs. 2C, 2D). In the sclera, KS immunostain-
ing was again markedly reduced, with both antibodies showing
KS as occurring in discrete concentrations within the tissue
(Figs. 2E, 2F).
Ultrastructure Distribution of BKS-1 and 5D4 in
Cornea, Limbus, and Sclera
The labeling of 5D4 was observed in the epithelium, basement
membrane (not shown), throughout the stroma (Fig. 3A), and
in keratocytes (Fig. 3B). There was a high density of KS-5D4 in
Bowman’s layer, stroma, and Descemet’s membrane but mod-
erate labeling in keratocytes. Figure 3 also shows the distribu-
tion of BKS-1 in Bowman’s layer (Fig. 3C), stroma (Fig. 3D), and
Descemet’s membrane (Fig. 3E). Labeling of the antibody was
strong in Bowman’s layer, stroma, and Descemet’s membrane,
similar to 5D4 labeling, but no labeling was seen in the epithe-
lium, basement membrane, keratocytes, or endothelium. A
moderate quantity of the antibody was present around the
keratocytes (Fig. 3F).
The labeling of 5D4 and BKS-1 was analyzed from the digital
images (Figs. 4A, 4B) processed (AnalySIS; Soft Imaging System
GmbH). Figure 5 shows the quantitative analysis of the anti-
body labeling at different depths in the central cornea. There
was a high density of KS-5D4 in Bowman’s layer and in the
anterior, middle, and posterior stroma, with no obvious differ-
ences between the regions. 5D4 labeled Descemet’s mem-
brane intensely, and the labeling was significantly higher (P 
0.001) than in the other four layers (Fig. 4C). The density of
KS-BKS-1 in the anterior stroma was higher than in the middle
and posterior stroma, but it was similar in Bowman’s layer and
Descemet’s layer (Fig. 4C). The intensity of 5D4 in all these
regions of the cornea was significantly higher (P  0.001) than
of BKS-1 (Fig. 4C).
In the limbal stroma, moderate labeling of 5D4 was ob-
served (Fig. 5A), but no labeling was seen in the limbal con-
junctiva. The distribution of the antibody was uniform through-
out the limbal stroma, and the labeling was less than that seen
in the cornea. In the sclera, the distribution of 5D4 was uni-
form but very low (Fig. 5C). Labeling of BKS-1 was also ob-
served in the limbal stroma (Fig. 5B) and sclera (Fig. 5D), but
FIGURE 3. Immunogold localization
of keratan sulfate with monoclonal
antibodies 5D4 and BKS-1 in normal
human cornea. (A) Strong labeling of
5D4 in the stroma. (B) Labeling of
5D4 in and around the keratocytes.
Labeling of BKS-1 in (C) Bowman’s
layer, (D) stroma, and (E) Descemet’s
membrane. (F) With BKS-1, no label-
ing was observed in the keratocytes.
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it was lower than in the cornea. The distribution of BKS-1 was
not uniform; rather, the label was aggregated in places. Figure
5E quantifies the reduction in labeling between the limbus and
the sclera using both antibodies.
DISCUSSION
Alteration in the structure of PGs in ocular tissue has previously
been assessed using antibodies against KS and dermatan sul-
fate. Monoclonal antibodies against KS have been useful in
identifying KS during normal corneal embryonic develop-
ment36 and in healing corneal wounds.37 Monoclonal antibod-
ies against KS-PG were also used to study the structural
changes in keratoconus.38,39
In the present studies both 5D4 and BSK-1 showed strong
labeling in the cornea and limbus but less in the sclera. Young
et al.40 showed that BKS-1 staining was lower than 5D4 stain-
ing in a single human cornea studied. We can now confirm that
this is the case and that it is true for all the regions (i.e.,
anterior, middle, and posterior stroma) of the cornea. 5D4
potentially recognizes several linear sulfation epitopes on a
single KS GAG, whereas BKS-1 only recognizes one neoepitope
per KS chain if that GAG chain has been susceptible to kera-
tanase digestion. This difference could be the reason there was
more labeling of 5D4 than of BKS-1 in the different tissues
examined.
Bettelheim41 investigated the glucosamine/galactosamine
ratio after chromatographic separation and showed that there
was a gradual increase in the ratio when proceeding from the
epithelium to the endothelium of bovine cornea. The glu-
cosamine/galactosamine ratio reflects the KS/chondroitin sul-
fate ratio of matrix GAGs in the cornea, and it was suggested
that a gradient of KS content in the cornea increased posteri-
orly. Scott and Haigh42 later reported that CS is produced in the
presence of large quantities of oxygen and that KS is produced
when oxygen is lacking, and it was suggested that KS stands in
for CS when the oxygen supply is low. To support this hypoth-
esis, it was shown that there was an increase in the quantity of
KS in the stroma of corneas from various species that corre-
lated with an increase in thickness.43 These studies were con-
ducted with the use of Alcian blue staining, in which only
sulfated groups on the KS glycosaminoglycans were stained.
In the present study, KS-specific antibody 5D4 showed only
a small difference in the KS-PG (sulfate) labeling between
anterior stroma and posterior stroma (not significant). On the
other hand, assuming that the same proportion of antigenic
sites was exposed in different sections, the differences in
anterior-posterior labeling with BKS-1 implies that there were
fewer KS-PG stubs in the posterior stroma than in the anterior
stroma, which in turn suggests that that fewer KS-PG GAG
chains were susceptible to keratanase digestion. Our results
may be reconciled with those of Bettelheim40 and Scott and
Haigh42 if we hypothesize that the posterior stroma, though
containing fewer BKS-1 detectible KS-GAG chains, comprises
chains that are longer or more oversulfated (i.e., 5D4 positive),
whereas the anterior stroma, though having more KS-PG
chains, contains chains that are relatively shorter or less sul-
fated than those in the posterior stroma.
Monoclonal antibodies such as 5D4 recognize numerous
linear pentasulfated hexasaccharide structures within one KS
chain, whereas BKS-1 recognizes a single neoepitope, the 6-sul-
fated N-acetyl glucosamine residue on the KS stubs after kera-
tanase digestion. Thus, BKS-1 labeling more accurately reveals
the presence of KS in the cornea, limbus, and sclera by recog-
nizing a single epitope on KS chains. The presence of a large
quantity of both antibodies reacting in the cornea suggests that
FIGURE 4. Digital images showing
examples of gold particle visualiza-
tion in the anterior stroma (A) using
5D4 and (B) BKS-1. (C) Graph show-
ing the distribution of gold-particle
labeling 5D4 and BKS-1 in different
layers of the central normal cornea.
Density of gold particles is expressed
as the number of particles per M2.
Bars represent SEM.
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KS-PGs, as well as KS, are more prevalent in the cornea than in
the limbus and sclera. The use of BKS-1 will be a helpful tool to
identify a more accurate and clearly defined pattern for KS not
only in the normal cornea but also in pathologic tissue such as
keratoconus.
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